C. Redfern
New England Journal of Medicine · 2006–2010
A researcher in the Science corpus: 2 papers; trusts 0 researchers and is trusted by 0 researchers here, as inferred from the citation graph.
Papers from C. Redfern's perspective
Ordered by how strongly the researchers C. Redfern trusts endorse each paper. Same corpus, a different order for every researcher.
- Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. (New England Journal of Medicine)
- Individual Comparisons by Ranking Methods
- Gene expression analysis of human prostate carcinoma during hormonal therapy identifies androgen-responsive genes and mechanisms of therapy resistance. (American Journal of Pathology)
- Increased expression of genes converting adrenal androgens to testosterone in androgen-independent prostate cancer. (Cancer Research)
- A randomized, placebo-controlled trial of zoledronic acid in patients with hormone-refractory metastatic prostate carcinoma. (Journal of the National Cancer Institute)
- Re: Abiraterone in metastatic prostate cancer without previous chemotherapy. (Journal of Urology)
- Development of the National Cancer Institute's patient-reported outcomes version of the common terminology criteria for adverse events (PRO-CTCAE). (Journal of the National Cancer Institute)
- Circulating Tumor Cells Predict Survival Benefit from Treatment in Metastatic Castration-Resistant Prostate Cancer (Clinical Cancer Research)
- Guidelines for the Evaluation of Immune Therapy Activity in Solid Tumors: Immune-Related Response Criteria (Clinical Cancer Research)
- Pazopanib versus sunitinib in metastatic renal-cell carcinoma. (New England Journal of Medicine)